Considering some data indicates parts of Europe has a much higher rate Dupuytrens this isn't good news for sales. Since they got Actelion as a partner in Canada I imagine they are the likely one to pick up Europe. I wonder if Pfizer didn't see the potential or didn't like the data for Peyronie's.
News 
Market Data 
Discover 
